The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial.
Vaccine
; 33(30): 3592-9, 2015 Jul 09.
Article
en En
| MEDLINE
| ID: mdl-26048780
ABSTRACT
BACKGROUND:
New, more effective vaccines to prevent tuberculosis (TB) disease are needed urgently. H4IC31 is an investigational vaccine that contains a fusion protein of the immunodominant antigens TB10.4 and Ag85B, formulated in IC31 adjuvant. We assessed the safety and immunogenicity of H4IC31 in South African adults from a TB endemic setting.METHODS:
In this double blind, placebo controlled, phase I trial, Mycobacterium tuberculosis-uninfected, HIV-uninfected, healthy adults with a history of childhood BCG vaccination were randomly allocated to two intramuscular vaccinations with 5, 15, 50 or 150 µg H4 formulated in 500nmol IC31, two months apart. Vaccinees were followed for six months to assess safety; immunogenicity was measured by ELISpot and intracellular cytokine staining assays.RESULTS:
Thirty-two participants received H4IC31 and 8 received placebo. Injection site adverse events were common but mild; mild fatigue was the most common systemic adverse event. Frequencies of adverse events did not differ between dosage groups. Detectable antigen-specific CD4 T cell responses were induced by all doses of H4IC31, but doses below 50 µg induced the highest frequencies of CD4 T cells, comprised predominantly of IFN-γ(+)TNF-α(+)IL-2(+) or TNF-α(+)IL-2(+) cells. These memory responses persisted up to the end of follow up, on study day 182.CONCLUSIONS:
H4IC31 demonstrated an acceptable safety profile and was immunogenic in South African adults. In this trial, the 15 µg dose appeared to induce the most optimal immune response.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Oligodesoxirribonucleótidos
/
Oligopéptidos
/
Linfocitos T CD4-Positivos
/
Vacunas contra la Tuberculosis
/
Mycobacterium tuberculosis
/
Antígenos Bacterianos
Tipo de estudio:
Clinical_trials
Límite:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
/
Middle aged
País como asunto:
Africa
Idioma:
En
Año:
2015
Tipo del documento:
Article